TuHURA Biosciences reports Q3 2026 results and clinical progress

TuHURA Biosciences announced its third‑quarter 2026 financials, showing cash holdings of $1.9 million at the end of September and $9.2 million raised from its Parkview credit facility. The company disclosed early data from an open‑label IFx‑2.0 study with Keytruda in metastatic Merkel cell carcinoma, where the first three patients achieved durable major responses. It also received FDA clearance to start a Phase 1b trial of its VISTA‑targeting antibody TBS‑2025 in a defined subset of relapsed/refractory AML. Executive Dr. James Bianco highlighted upcoming poster presentations on Delta Opioid Receptor technology at the December ASH meeting.

The cash balance and fresh financing give the firm runway to fund its clinical programs without diluting shareholders, according to the company’s statement. FDA clearance for the TBS‑2025 study enables the next step toward potential accelerated approval, which could increase the company’s valuation if early data are positive.

  • 1Cash and cash equivalents were $1.9 million at September 30, 2026.
  • 2The Parkview credit facility provided $9.2 million in gross proceeds, of which $5.6 million was drawn during the quarter.
  • 3Research and development expenses for the quarter were $3.7 million.
  • 4Operating cash outflows for the nine‑month period ended September 30, 2026 were $18.1 million.
  • 5The first three patients in the IFx‑2.0 plus Keytruda study showed major objective partial responses lasting more than six months.
  • 6The FDA issued an IND clearance and a “Study May Proceed” notice for a Phase 1b trial of TBS‑2025 in relapsed/refractory mutNPM1 AML.

Sources